Europe Insulin Pump Market Size, Share & COVID-19 Impact Analysis, By Product Type (Pumps [Tethered Pumps, Patch Pumps, and Others] and Consumables), By Disease Indication (Type 1 Diabetes and Type 2 Diabetes), By Distribution Channel (Hospital Pharmacy and Retail & Online Pharmacy), and Regional Forecast, 2023-2030

Europe is the second largest region in the global insulin pump market. The Europe insulin pump market size is projected to record a CAGR of 16.5% during the forecast period. The global insulin pump market is projected to grow from USD 4.60 billion in 2022 to USD 15.51 billion by 2030.

The rising incidence of type 1 diabetes among adults in Europe has increased the need for insulin and its delivery devices, such as insulin pumps, among the diabetic population. As per the International Diabetes Federation (IDF) Atlas factsheet in 2021, about 295,000 children and adolescents were suffering from type 1 diabetes in Europe.

This report on the Europe insulin pump market covers the following countries/regions – U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe.

LATEST TRENDS

Extensive Presence of Insulin Pump Manufacturers to Offer New Market Growth Opportunities

The need for insulin delivery devices, such as insulin pumps, is high owing to the rising prevalence of type 1 diabetes among adolescents in Europe. Also, the vast presence of insulin pump manufacturers enhanced the adoption of insulin therapy in the region, which will drive the market growth. Moreover, extensive presence of distribution channels for the supply of these pumps by major regional players is expected to fuel the market growth.

• In September 2020, Insulet Corporation announced that it had received the extensive approval for its Omnipod DASH Insulin Management System across Europe, primarily in the U.K., Italy, Sweden, Finland, Norway, and Denmark.

DRIVING FACTORS

Rising Number of Joint Ventures and Start-ups to Propel Product Demand

The demand for insulin and insulin pumps is increasing due to the rising need for diabetes care and management among the patient population. Thus, several market players are emphasizing on implementing various strategic initiatives, such as collaborations and acquisitions to develop technologically advanced products. Such initiatives will propel the introduction of and demand for new pumps, further fostering solid opportunities for the market’s growth during the forecast period.

• In April 2022, Abbott, CamDiab, and Ypsomed announced that they were teaming up to develop and commercialize an integrated Automated Insulin Delivery (AID) system to help lessen the burden of round-the-clock diabetes management for people living with the disease. The initial focus of the partnership was expected to be on European countries.

RESTRAINING FACTORS

High Proportion of Undiagnosed Diabetes Population to Decrease Adoption of Insulin Pumps

A large proportion of the European population remains undiagnosed for diabetes due to the long detection period and lack of symptoms among patients, especially those suffering from Type 2 diabetes. Moreover, lack of awareness about the disease among the general population and healthcare providers, and limited government screening programs have also increased the percentage of unidentified diabetes patients. Thus, vast presence of the undiagnosed population is limiting the demand for and adoption of diabetes care systems, such as insulin pumps in Europe, further hampering the market growth.

• As per the International Diabetes Federation (IDF) estimates, in 2021, 35.7% (21.9 million) of the Europe population remained undiagnosed with diabetes.

KEY INDUSTRY PLAYERS

The Europe market comprises dominant players such as Medtronic and Insulet Corporation. The dominance was due to their robust product offerings, high adoption, and strong regional distribution network, which are contributing to the market's growth.

• In April 2021, Medtronic launched its extended infusion set in selected European countries, such as Finland and Belgium, which can be used for a period of up to seven days. The infusion set was developed in partnership with ConvaTec's Unomedical subsidiary, Convatec Infusion Care.

Other prominent players, such as Terumo Corporation and CeQur Simplicity, are also leading the market due to rising R&D investments and strategic collaborations & partnerships among the players to increase the Europe insulin pump market share.

LIST OF KEY COMPANIES PROFILED:

• Medtronic (Ireland)


• Tandem Diabetes Care, Inc. (U.S.)


• Insulet Corporation (U.S.)


• ViCentra B.V. (Netherlands)


• F. Hoffmann-La Roche Ltd (Switzerland)


• Terumo Corporation (Japan)


• CeQur Simplicity (Switzerland)


• Microtec Medical Ltd (U.K.)

KEY INDUSTRY DEVELOPMENTS:

• December 2022: Tandem Diabetes Care, Inc. announced a collaboration with AMF Medical SA, a Swiss company, to double its diabetes technology offerings of insulin pumps instantly.


• March 2022: Terumo Corporation and Glooko, Inc., a global leader in data management, announced a technology-based partnership to deliver new diabetes data-sharing solutions globally. This new integration enabled people with diabetes to transfer recorded data from MEDISAFE WITH insulin patch pump to the Glooko platform.

REPORT COVERAGE

The report provides a detailed market analysis. It focuses on key aspects, such as the launch of new products, technological advancements, and the prevalence of diabetes. Besides this, the report offers important insights into the recent market trends and highlights key industry developments such as mergers, partnerships, and acquisitions, and the effect of COVID-19 on the market. In addition to the above-mentioned factors, the report encompasses several factors that have contributed to the market growth in recent years.

Report Scope & Segmentation